TAT 2018 - Targeted Anticancer Therapies

Oncology Meeting Resources

05 Mar - 07 Mar 2018, Paris, France

TAT 2018

TAT 2018 - Targeted Anticancer Therapies focuses on early-phase development and translational research. The programme covered targeted agents, immuno-oncology and combinations involving such agents. Presentations and webcasts from the TAT 2018 - Targeted Anticancer Therapies are available here to ESMO members.

Watch ESMO video reports from experts:

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programme | Future ESMO meetings





Format available

https://oncologypro.esmo.org/Meeting-Resour...nticancer-Therapies/Glioma-and-IDH-targeting

Approximately 80% of WHO grade II and III gliomas, and secondary glioblastomas (representing 25% of adult diffuse gliomas overall) harbor mutations in the metabolic isocitrate dehydrogenase enzymes encoded by the IDH1/2 genes.

Date: 06 Mar 2018
Presenter: Daniel Cahill
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Central Nervous System Malignancies

https://oncologypro.esmo.org/Meeting-Resour...-a-metabolic-co-dependency-for-brain-cancers

Oncogenic mutations in growth factor receptor signaling pathways are common in cancer, including in tumors that arise from or metastasize to the brain. However, most small-molecule inhibitors targeting...

Date: 06 Mar 2018
Presenter: Genaro Villa
Resources: Abstract
Topics: Biomarkers, Central Nervous System Malignancies, Translational Research

https://oncologypro.esmo.org/Meeting-Resour...-cell-metabolism-and-metabolic-reprogramming

Date: 06 Mar 2018
Presenter: Jonathan Powell
Resources: Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...ginine-Deprivation-in-ASS1-Deficient-Cancers

Argininosuccinate Synthetase 1 (ASS1) is silenced in ∼90% of sarcomas. Loss of this urea cycle enzyme causes cells to become dependent upon extracellular arginine for continued cell growth and proliferation.

Date: 06 Mar 2018
Presenter: Brian Van Tine
Resources: Abstract, Presentation, Webcast
Topic: Palliative and Supportive Care

https://oncologypro.esmo.org/Meeting-Resour...-and-immunotherapy-Synergies-of-combinations

In cancer the presence of T cell immune infiltration has been recognised as a prognostic factor, however the mechanisms underpinning this response are not clearly defined.

Date: 06 Mar 2018
Presenter: Richard Kennedy
Resources: Abstract, Presentation
Topic: Cancer Immunology and Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...ays-to-harness-targeting-DNA-to-treat-cancer

Date: 06 Mar 2018
Presenter: Ruth Plummer
Resources: Presentation, Webcast
Topics: Biomarkers, Translational Research

https://oncologypro.esmo.org/Meeting-Resour...cer-Therapies/Novel-topoisomerase-inhibitors

DNA topoisomerases are validated targets for a broad range of widely used anticancer drugs. They include the topoisomerase II (TOP2) inhibitors, etoposide, teniposide, doxorubicin, daunorubicin and...

Date: 06 Mar 2018
Presenter: Yves Pommier
Resources: Abstract, Presentation

https://oncologypro.esmo.org/Meeting-Resour...herapies/Targeting-the-DDR-DNA-PK-inhibition

Deoxyribonucleic acid-dependent protein kinase (DNA-PK) plays a critical role in the repair of DNA double strand break (DSBs). DNA double stranded breaks are the most lethal type of DNA lesion, and...

Date: 06 Mar 2018
Presenter: Frank Zenke
Resources: Abstract
Topic: Anti-Cancer Agents & Biologic Therapy

https://oncologypro.esmo.org/Meeting-Resour...of-CDK4-6-inhibition-Induction-of-senescence

CDK4/6 inhibitors are being used to treat a variety of human malignancies. In well-differentiated (WDLS) and dedifferentiated (DDLS) liposarcoma we had previously suggested that their clinical promise...

Date: 07 Mar 2018
Presenter: Andrew Koff
Resources: Abstract, Presentation

https://oncologypro.esmo.org/Meeting-Resour...-combination-with-immune-checkpoint-blockade

While immune checkpoint inhibitors (ICI) are efficacious and lead to durable responses in patients with various cancers, only a minority of patients respond. An approach to increase the efficacy of ICI...

Date: 07 Mar 2018
Presenter: Patrick Roberts
Resources: Abstract